Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
Narrative review supports SGLT-2i use in cardiovascular-kidney-metabolic syndrome
New Treatment Shifts How We Fight Heart, Kidney, and Diabetes Damage
This narrative review summarizes evidence on SGLT-2 inhibitors for patients with stages 2–4 cardiovascular-kidney-metabolic syndrome.
Maria, 58, has type 2 diabetes and high blood pressure.
Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD
SGLT2 inhibitors lower kidney failure risk in type 2 diabetes patients
This systematic review and meta-analysis of 10 studies synthesized evidence on dapagliflozin for renal outcomes in patients with type 2 diab…
A review of ten studies shows these drugs reduce kidney failure risk in people with type 2 diabetes and kidney disease.
Systematic review links hypertension, diabetes, and pulmonary inflammation; SGLT2 inhibitors show potential
Why Your Blood Pressure Might Be Hurting Your Lungs
This systematic review of 48 articles explores the interplay between arterial hypertension, diabetes mellitus, and pulmonary inflammation.
High blood pressure and diabetes don't just affect your heart and sugar levels; they team up to harm your lungs.
Jordan guideline review highlights SGLT2 inhibitor access barriers for heart failure patients
Heart Failure Patients Face New Insurance Hurdle for Key Drug
This mixed-methods study and guideline analysis surveyed 312 physicians in Jordan regarding prescribing decisions and insurance authorizatio…
A new study reveals that insurance rules, not medical science, are stopping heart failure patients from getting a proven treatment.
Computational model review predicts dual optima for combination therapy in ageing
New math model shows combining drugs could slow aging better than weight loss alone
This review of a computational model explores combination therapy with semaglutide, SGLT2 inhibitors, metformin, and rapamycin for ageing.
A new computer model reveals that fixing blood sugar and slowing aging are separate tasks, meaning some drugs might help you live longer eve…
Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
No More Bone Fear With New Diabetes Drug
This meta-analysis evaluated adjunctive SGLT2 inhibitor therapy in 6,731 patients with type 1 diabetes mellitus receiving insulin-based ther…
Many people with type 1 diabetes worry about their bones.
Meta-analysis of 13 trials finds SGLT2 inhibitors reduce heart failure hospitalization in myocardial infarction
New Drug Combo Lowers Heart Failure Risk After Heart Attack
This meta-analysis synthesizes data from 13 randomized controlled trials involving 22,238 patients with myocardial infarction.
Adding a specific diabetes medication to standard heart care may prevent future heart failure after a heart attack.
Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
Semaglutide Does Not Raise Suicide Risk, Study Finds
This active-comparator, new-user target trial emulation review synthesizes data from 102,361 U.S.
A large new study finds that semaglutide does not increase suicide risk compared to other diabetes drugs, easing fears for millions of patie…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
Bayesian network meta-analysis evaluates antidiabetic medications and dementia risk in 4,382,897 patients
Could diabetes drugs lower dementia risk, or raise it for some patients?
This Bayesian network meta-analysis synthesized data from 28 articles involving 4,382,897 patients to assess antidiabetic drugs and dementia…
Insulin and metformin cut dementia risk, but DPP4 inhibitors may double Alzheimer's risk compared to SGLT2 drugs in diabetes patients.
SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
Taking More Heart Pills May Actually Feel Better, Not Worse
A cross-sectional study of 78 heart failure patients in a Malaysian MTAC program found SGLT2i users had significantly lower adherence (p = 0…
Heart failure patients taking more heart medicines reported feeling better, not worse, in a new study from Malaysia.